Valuation: Acrux Limited

Market Cap 66.72L 45.91L 40.2L 37.11L 34.66L 65.24L 43Cr 4.47Cr 1.72Cr 21Cr 1.72Cr 1.69Cr 74Cr P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 94.44L 64.99L 56.9L 52.53L 49.05L 92.34L 61Cr 6.32Cr 2.44Cr 30Cr 2.44Cr 2.39Cr 105.24Cr EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-7.14%
1 week-13.33%
Current month+8.33%
3 months+8.33%
6 months-13.33%
Current year-13.33%
1 week 0.01
Extreme 0.013
0.02
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-13.33%-23.53%-69.05% 49.61L
+0.64%+1.99%+11.09%+83.48% 4.74TCr
+0.79%+3.76%+53.94%+103.77% 3.55TCr
+0.97%+7.57%-3.21%+43.98% 1.23TCr
+1.81%+4.72%+14.21%+92.51% 1.16TCr
-2.10%+0.38%+36.72%+126.29% 888.1Cr
-1.55%+1.77%+20.70%+42.00% 720.73Cr
+1.37%+7.16%+55.99%-9.35% 691.07Cr
+1.49%-1.22%+27.78%+223.65% 644.5Cr
+9.12%+8.29%-29.64%+5.21% 494.11Cr
Average +0.54%+2.51%+16.40%+64.25% 1.41TCr
Weighted average by Cap. +0.89%+3.14%+24.50%+85.56%

Financials

2024 2025
Net sales 50.91L 35.03L 30.67L 28.32L 26.44L 49.78L 33Cr 3.41Cr 1.32Cr 16Cr 1.32Cr 1.29Cr 57Cr 11.9L 8L 7L 7L 6L 11.63L 7.74Cr 79.65L 30.75L 3.82Cr 30.75L 30.08L 13Cr
Net income -58L -39.91L -34.94L -32.26L -30.12L -56.71L -38Cr -3.88Cr -1.5Cr -19Cr -1.5Cr -1.47Cr -65Cr -59.45L -40.91L -35.82L -33.07L -30.88L -58.13L -39Cr -3.98Cr -1.54Cr -19Cr -1.54Cr -1.5Cr -66Cr
Net Debt 8L 5L 5L 4L 4L 7L 4.94Cr 50.8L 19.61L 2.44Cr 19.61L 19.18L 8.46Cr 27.72L 19.07L 16.7L 15.42L 14.4L 27.1L 18Cr 1.86Cr 71.63L 8.9Cr 71.63L 70.06L 31Cr
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
29/26/29 A$0.0130 -7.14% 2,37,052
26/26/26 A$0.0140 +7.69% 7,89,030
25/26/25 A$0.0130 -7.14% 13,27,517
24/26/24 A$0.0140 +7.69% 3,69,855
23/26/23 A$0.0130 -7.14% 22,04,776

Annual profits - Rate of surprise